A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.

In the Immune Tolerance Network's (ITN) HALT-MS study, 24 patients with relapsing, remitting multiple sclerosis received high-dose immunosuppression followed by a transplant of their own stem cells, called an autologous stem cell transplant, to potentially reprogram the immune system so that it stops attacking the brain and spinal cord. Data published in the Journal of Clinical Investigation quantified and characterized T cell populations following this aggressive regimen to understand how the reconstituting immune system is related to patient outcomes.

ITN investigators used a high-throughput, deep-sequencing technology (Adaptive Biotechnologies, ImmunoSEQTM Platform) to analyze the T cell receptor (TCR) sequences in CD4+ and CD8+ cells to compare the repertoire at baseline pre-transplant, two months post-transplant and 12 months post-transplant.

Using this approach, alongside conventional flow cytometry, the investigators found that CD4+ and CD8+ lymphocytes exhibit different reconstitution patterns following transplantation. The scientists observed that the dominant CD8+ T cell clones present at baseline were expanded at 12 months post-transplant, suggesting these clones were not effectively eradicated during treatment. In contrast, the dominant CD4+ T cell clones present at baseline were undetectable at 12 months, and the reconstituted CD4+ T cell repertoire was predominantly composed of new clones.

The results also suggest the possibility that differences in repertoire diversity early in the reconstitution process might be associated with clinical outcomes. Nineteen patients who responded to treatment had a more diverse repertoire two months following transplant compared to four patients who did not respond. Despite the low number of non-responders, these comparisons approached statistical significance and point to the possibility that complexity in the T cell compartment may be important for establishing immune tolerance.

This is one of the first studies to quantitatively compare the baseline T cell repertoire with the reconstituted repertoire following autologous stem cell transplant, and provides a previously unseen in-depth analysis of how the immune system reconstitutes itself following immune-depleting therapy.

About The Immune Tolerance Network

The Immune Tolerance Network (ITN) is a research consortium sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The ITN develops and conducts clinical and mechanistic studies of immune tolerance therapies designed to prevent disease-causing immune responses, without compromising the natural protective properties of the immune system. Visit http://www.immunetolerance.org for more information.

Story Source:

The above story is based on materials provided by Immune Tolerance Network. Note: Materials may be edited for content and length.

Read more:
Deep TCR sequencing reveals extensive renewal of the T cell repertoire following autologous stem cell transplant in MS

PUBLIC RELEASE DATE:

17-Feb-2014

Contact: Philip Bernstein, Ph.D. ITNCommunications@immunetolerance.org 240-235-6132 Immune Tolerance Network

WA, Seattle (February 17, 2014) A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.

In the Immune Tolerance Network's (ITN) HALT-MS study, 24 patients with relapsing, remitting multiple sclerosis received high-dose immunosuppression followed by a transplant of their own stem cells, called an autologous stem cell transplant, to potentially reprogram the immune system so that it stops attacking the brain and spinal cord. Data published today in the Journal of Clinical Investigation quantified and characterized T cell populations following this aggressive regimen to understand how the reconstituting immune system is related to patient outcomes.

ITN investigators used a high-throughput, deep-sequencing technology (Adaptive Biotechnologies, ImmunoSEQTM Platform) to analyze the T cell receptor (TCR) sequences in CD4+ and CD8+ cells to compare the repertoire at baseline pre-transplant, two months post-transplant and 12 months post-transplant.

Using this approach, alongside conventional flow cytometry, the investigators found that CD4+ and CD8+ lymphocytes exhibit different reconstitution patterns following transplantation. The scientists observed that the dominant CD8+ T cell clones present at baseline were expanded at 12 months post-transplant, suggesting these clones were not effectively eradicated during treatment. In contrast, the dominant CD4+ T cell clones present at baseline were undetectable at 12 months, and the reconstituted CD4+ T cell repertoire was predominantly comprised of new clones.

The results also suggest the possibility that differences in repertoire diversity early in the reconstitution process might be associated with clinical outcomes. Nineteen patients who responded to treatment had a more diverse repertoire two months following transplant compared to four patients who did not respond. Despite the low number of non-responders, these comparisons approached statistical significance and point to the possibility that complexity in the T cell compartment may be important for establishing immune tolerance.

This is one of the first studies to quantitatively compare the baseline T cell repertoire with the reconstituted repertoire following autologous stem cell transplant, and provides a previously unseen in-depth analysis of how the immune system reconstitutes itself following immune-depleting therapy.

###

Read the original post:
Extensive renewal of the T cell repertoire following autologous stem cell transplant in MS

Contact Information

Available for logged-in reporters only

Newswise WA, Seattle (February 17, 2014) A new study describes the complexity of the new T cell repertoire following immune-depleting therapy to treat multiple sclerosis, improving our understanding of immune tolerance and clinical outcomes.

In the Immune Tolerance Networks (ITN) HALT-MS study, 24 patients with relapsing, remitting multiple sclerosis received high-dose immunosuppression followed by a transplant of their own stem cells, called an autologous stem cell transplant, to potentially reprogram the immune system so that it stops attacking the brain and spinal cord. Data published today in the Journal of Clinical Investigation (http://www.jci.org/articles/view/71691?key=b64763243f594bab6646) quantified and characterized T cell populations following this aggressive regimen to understand how the reconstituting immune system is related to patient outcomes.

ITN investigators used a high-throughput, deep-sequencing technology (Adaptive Biotechnologies, ImmunoSEQTM Platform) to analyze the T cell receptor (TCR) sequences in CD4+ and CD8+ cells to compare the repertoire at baseline pre-transplant, two months post-transplant and 12 months post-transplant.

Using this approach, alongside conventional flow cytometry, the investigators found that CD4+ and CD8+ lymphocytes exhibit different reconstitution patterns following transplantation. The scientists observed that the dominant CD8+ T cell clones present at baseline were expanded at 12 months post-transplant, suggesting these clones were not effectively eradicated during treatment. In contrast, the dominant CD4+ T cell clones present at baseline were undetectable at 12 months, and the reconstituted CD4+ T cell repertoire was predominantly comprised of new clones.

The results also suggest the possibility that differences in repertoire diversity early in the reconstitution process might be associated with clinical outcomes. Nineteen patients who responded to treatment had a more diverse repertoire two months following transplant compared to four patients who did not respond. Despite the low number of non-responders, these comparisons approached statistical significance and point to the possibility that complexity in the T cell compartment may be important for establishing immune tolerance.

This is one of the first studies to quantitatively compare the baseline T cell repertoire with the reconstituted repertoire following autologous stem cell transplant, and provides a previously unseen in-depth analysis of how the immune system reconstitutes itself following immune-depleting therapy.

About The Immune Tolerance Network The Immune Tolerance Network (ITN) is a research consortium sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The ITN develops and conducts clinical and mechanistic studies of immune tolerance therapies designed to prevent disease-causing immune responses, without compromising the natural protective properties of the immune system. Visit http://www.immunetolerance.org for more information.

###

Read this article:
Deep TCR Sequencing Reveals Extensive Renewal of the T Cell Repertoire Following Autologous Stem Cell Transplant in ...

StemCells, Inc. Expands Phase I/II Spinal Cord Injury Trial to North America

NEWARK, Calif., Jan. 10, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that a team at the University of Calgary successfully transplanted its first subject in the Company's Phase I/II clinical trial in chronic spinal cord injury, with the Company's proprietary HuCNS-SC human neural stem cells. The ninth subject to enroll in the trial, which was initiated in Switzerland, is the first spinal cord injury patient to have undergone transplantation in North America. This expansion from a single-site, single-country study to a multi-site, multi-country program accelerates the current trial, which should complete enrollment of the remaining three patients this quarter, and pave the way for a controlled Phase II efficacy study that StemCells, Inc. plans to initiate mid-year to further investigate its HuCNS-SC product candidate as a treatment for spinal cord injury.

"With this transplantation in Canada, we have the first international trial investigating neural stem cells for spinal cord injury," said Stephen Huhn, M.D., FACS, FAAP, Vice President, CNS Clinical Research at StemCells, Inc. "The 12-month data from the first cohort has demonstrated a favorable safety profile, and sensory gains first detected in two of the three subjects at the six-month assessment have persisted. The third subject remains stable. We are extremely encouraged with the progress of our spinal cord injury program and the transition into an international study will accelerate completion of enrollment."

Steve Casha, M.D., Ph.D., FRCSC, the principal investigator at the University of Calgary, added, "We are proud to be the first center to enroll a subject in North America. This important research is yielding critical insight into the use of stem cells in treating spinal cord injury patients. The results should serve as a solid foundation for the Company's planned Phase II controlled efficacy study and represents an important step in the development of this promising technology."

"We have closely followed the conduct of the StemCells, Inc. trial at the University of Zurich, under the direction of Dr. Armin Curt," said Michael Fehlings M.D., Ph.D., FACS, FRCSC. Dr. Fehlings is Medical Director of the Krembil Neuroscience Centre, Professor of Neurosurgery at the University of Toronto, head of the Spinal Program at the Toronto Western Hospital, and principal investigator for the trial at the University of Toronto. "There is a large unmet medical need for treatments in spinal cord injury. The opening of sites in North America is great news for the worldwide community of patients and their families, as well as for researchers. There is a strong rationale to explore novel therapeutic approaches to treating spinal cord injury, and we are pleased to be working with StemCells at the forefront of this trailblazing study."

About the StemCells, Inc. Spinal Cord Injury Clinical Trial

The Company's Phase I/II clinical trial is designed to assess both safety and preliminary efficacy of HuCNS-SC cells as a treatment for chronic spinal cord injury. The Company plans to enroll 12 subjects with thoracic (chest-level) neurological injuries at the T2-T11 level, classified as complete or incomplete according to the American Spinal Injury Association Impairment Scale.

To date, nine patients have been enrolled and transplanted with HuCNS-SC cells.Each of the first three subjects suffered a complete injury prior to enrolling in the study. Twelve months after transplantation of the HuCNS-SC cells, data showed multi-segment gains in sensory function in two of the first three subjects, one of which converted from a complete injury classification to an incomplete injury.The third subject in this cohort remained stable, 12 months after transplantation. The company expects to report additional interim data on both the first and second cohorts by mid-2014.

The trial is currently enrolling spinal cord injury patients at three centers: the University of Calgary; the University of Toronto; and at Balgrist University Hospital, University of Zurich, a world-leading medical center for spinal cord injury and rehabilitation. Patients who may qualify and are interested in participating in the study in North America should contact the University of Calgary at 403-944-4334 or the University of Toronto at 416-603-5285. For information on enrollment in Switzerland, interested parties may contact the study nurse either by phone at +41 44 386 39 01, or by email at stemcells.pz@balgrist.ch.

All subjects who enroll in the trial will receive HuCNS-SC cells through direct transplantation into the spinal cord and will undergo temporary treatment with immunosuppressive drugs.Evaluations will be regularly performed in the post-transplant period in order to monitor and assess the safety of the HuCNS-SC cells, the surgery and the immunosuppression, as well as to measure any change in neurological function.Preliminary efficacy will be evaluated based on defined clinical endpoints, such as changes in sensation, motor function and bowel/bladder function.The Company intends to follow the effects of this intervention long term, and each of the subjects will be invited to enroll in a separate four-year observational study after completing the Phase I/II study.In addition, the Company plans to initiate a controlled Phase II efficacy trial in in spinal cord injury in 2014.

Continue reading here:
StemCells, Inc. Expands Phase I/II Spinal Cord Injury ...

By Matt Richardson Photos by Ed Mulholland

Junior middleweight Boyd Melson has a fight scheduled for tomorrow night at the Roseland Ballroom in Manhattan against Donald Ward. Its a fight that Melson (13-1-1, 4 KOs) says he expects will be difficult, despite Ward being a late replacement for veteran Mike Ruiz. Its a fight, however, thats relatively small in relation to the one Melson fights on a daily basis.

Thats because Melson, an Army captain in the U.S. Army Reserves, is also battling a much tougher foe: spinal cord injuries. As a boxer who donates his full purses to spinal cord research, its easy to say he has a dog in this fight and its one where hes continuing to punch, despite the odds.

Were trying to bring awareness to spinal cord injuries and fund a clinical trial to happen here in the U.S, explained Melson. Theres a clinical trial thats going to be happening at the end of this year that a doctor named Dr. Wise Young is working on. Hes doing a trial here hopefully in New York and New Jersey, before this year is out, where hes going to be using umbilical cord cells and injecting them into the spinal cord. He already did this in China and hes using that data to get FDA approval here.

15 out of the 20 patients he did that were paralyzed after seven years, one of them was as long as 19 years paralyzed, Melson continued. But 15 out of the 20 are walking now with a walker and no human assistance. Its out of this world. Its a miracle. Its real frustrating for me to know that in another part of the world we may have a cure for this and its not here yet. It stinks.

Despite his being profiled in a series of publications and television programs, Melson said theres still a way to go in matching the awareness of the issue to a potential cure.

Its still a big fight, he admitted. Maybe, locally in New York people know about it. Or theyll just know that I donate my purses. A lot of them think its stem cell research, which is not correct. That happened because theyre taking stem cells from the umbilical cord for this study but theyre adult stem cells. They were donated after the baby was born. But there are plenty of different types of therapies people are using, going outside stem cells. This one just happens to be using it but its to cure paralysis, not to study stem cells.

Melson isnt alone in his aim to obtain more spinal cord injury research and has even secured the support of a series of other fighters, including Steve Cunningham, Demetrius Andrade, Deandre Latimore, Edgar Santana and Danny Jacobs on his Team Fight to Walk.

Those are some pretty strong names right there, he said.

Hes right.

See more here:
Melson keeps fighting

Up To 500,000 Spinal Cord Injuries Per Year Worldwide The World Health Organization says as many as 500,000 people suffer spinal cord injuries every year. And it says people with such injuries are much more likely to die early. Recently, the World Health Organization released a report called International Perspectives on Spinal Cord Injuries. Alana Officer works at the WHO. She says spinal cord injuries do more than just cause paralysis, or lack of movement. There are a lot more associated health problems, such as difficulty with bowel and bladder function, difficulty with sexual function, associated problems around mental health conditions. So its much broader than just experiencing paralysis. Alana Officer is the WHOs Coordinator for Disability and Rehabilitation. She says the main causes of spinal cord injuries are traffic accidents, falls and violence. She says some causes are more common in certain areas. For example, road traffic crashes are the main contributors of spinal cord injury in Africa and the Western Pacific region. Falls tend to be the leading cause in Southeast Asia and the Middle East. And then we have high rates of violence in certain countries. We have high rates in the U.S. We have high rates in South Africa. And then weve also got the non-traumatic causes of spinal cord injuries, such as tumors and cancers, tuberculosis and spinabifida. Most people think of tuberculosis as a lung disease. But in some African countries, it is responsible for about one third of the non-violent spinal cord injuries. The birth defect spinabifida causes damage to the spine. In severe cases, it can affect walking and daily activities. Health officials say they do not yet know the exact cause of spinabifida. But they say it may be linked to genes and the environment. Alana Officer says more men than women suffer spinal cord injuries. Theres a ratio of about two-to-one of males to females. Men tend to be more likely to experience spinal cord injury between the ages of about 20 and 29 -- women, or certainly girls much younger, between sort of 15 and 19. So thats our first peak in young people. And then we get a second peak, interestingly, in older people. And the major driver of that is falls, tumors, cancer, et cetera. She says the main reason people with spinal cord injuries are more likely to die early is lack of medical care. A lot of people with spinal cord injuries, certainly in low- and middle- income countries, do not get appropriate emergency response care. Mortality rates are very strongly affected by the quality of the health care system. For example, if youre in a low-income country, you are three times more likely of dying in (a) hospital following a spinal cord injury than you would be in a high-income country. Ms. Officer says many of the causes of spinal cord injury deaths in poor countries are preventable. These include urinary tract infections and pressure sores, also known as bedsores. These are areas of damaged skin caused by a person staying in one position too long. Bedsores are usually not life-threatening problems in wealthy countries. People with spinal cord injuries can live pretty much the same amount of time as somebody without a spinal cord injury. Theres a slight difference, but certainly life expectancy has increased considerably in high-income countries. And its not the case in low- income countries. Experts suggest immediate action if a spinal cord injury is suspected, including immobilization of the spine, restricting its movement. The WHO says that should be followed by what it calls, care appropriate to the level and severity of the injury, degree of instability of the spine and compression of nerves. It also suggests skilled rehabilitation and mental health services. The WHO notes that up to 30 percent of people with spinal cord injuries show clinically-significant signs of depression. There is currently no cure for paralysis from spinal cord injuries, but many researchers are looking for one. Alana Officer says there is much that can be done to prevent such injuries -- including building safer roads and vehicles, reducing drinking and driving and wearing seatbelts. Other measures include improving safety in sports and the workplace, and adding window guards to windows. She says spinal cord injuries would be reduced if doctors could identify and treat tuberculosis earlier and by improving nutrition to reduce spinabifida cases. Scientists Create Lung Tissue from Stem Cells Finally, scientists have used stem cell technology to create working lung cells. Researchers say stem cells also could be used to create new drugs to treat diseases that restrict breathing. And they think the cells could one day create tissue for lung transplant operations. The research is another step toward what is being called personalized medicine. Over the past several years, scientists have used stem cells and growth factors to force the bodys master cells to create other cells. This process has created heart, intestinal, liver, nerve and insulin-producing cells as possible replacements for diseased organs.

x

Continued here:
New Brain-Image Database Could Help People With Chronic Pain

Contact Information

Available for logged-in reporters only

Newswise NEW YORK, NY (February 6, 2014) In most cases of amyotrophic lateral sclerosis (ALS), or Lou Gehrigs disease, a toxin released by cells that normally nurture neurons in the brain and spinal cord can trigger loss of the nerve cells affected in the disease, Columbia researchers reported today in the online edition of the journal Neuron.

The toxin is produced by star-shaped cells called astrocytes and kills nearby motor neurons. In ALS, the death of motor neurons causes a loss of control over muscles required for movement, breathing, and swallowing. Paralysis and death usually occur within 3 years of the appearance of first symptoms.

The report follows the researchers previous study, which found similar results in mice with a rare, genetic form of the disease, as well as in a separate study from another group that used astrocytes derived from patient neural progenitor cells. The current study shows that the toxins are also present in astrocytes taken directly from ALS patients.

I think this is probably the best evidence we can get that what we see in mouse models of the disease is also happening in human patients, said the studys senior author, Serge Przedborski, MD, PhD, the Page and William Black Professor of Neurology (in Pathology and Cell Biology), Vice Chair for Research in the Department of Neurology, and co-director of Columbias Motor Neuron Center.

The findings also are significant because they apply to the most common form of ALS, which affects about 90 percent of patients. Scientists do not know why ALS develops in these patients; the other 10 percent of patients carry one of 27 genes known to cause the disease.

Now that we know that the toxin is common to most patients, it gives us an impetus to track down this factor and learn how it kills the motor neurons, Dr. Przedborski said. Its identification has the potential to reveal new ways to slow down or stop the destruction of the motor neurons.

In the study, Dr. Przedborski and study co-authors Diane Re, PhD, and Virginia Le Verche, PhD, associate research scientists, removed astrocytes from the brain and spinal cords of six ALS patients shortly after death and placed the cells in petri dishes next to healthy motor neurons. Because motor neurons cannot be removed from human subjects, they had been generated from human embryonic stem cells in the Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research, also at CUMC.

Within two weeks, many of the motor neurons had shrunk and their cell membranes had disintegrated; about half of the motor neurons in the dish had died. Astrocytes removed from people who died from causes other than ALS had no effect on the motor neurons. Nor did other types of cells taken from ALS patients.

Read the original post:
Toxin from Brain Cells Triggers Neuron Loss in Human ALS Model

New details about how motor neurons die in ALS have been uncovered by a new cell-culture system that combines spinal cord or brain cells from ALS patients with human motor neurons. The culture system shows that patient astrocytes (shown here with a blue-stained nucleus) release a toxin that kills motor neurons via a recently discovered process described as a controlled cellular explosion. Image: Diane Re.

NEW YORK, NY (February 6, 2014) In most cases of amyotrophic lateral sclerosis (ALS), or Lou Gehrigs disease, a toxin released by cells that normally nurture neurons in the brain and spinal cord can trigger loss of the nerve cells affected in the disease, Columbia researchers reported today in the online edition of the journal Neuron.

The toxin is produced by star-shaped cells called astrocytes and kills nearby motor neurons. In ALS, the death of motor neurons causes a loss of control over muscles required for movement, breathing, and swallowing. Paralysis and death usually occur within 3 years of the appearance of first symptoms.

The report follows the researchers previous study, which found similar results in mice with a rare, genetic form of the disease, as well as in a separate study from another group that used astrocytes derived from patient neural progenitor cells. The current study shows that the toxins are also present in astrocytes taken directly from ALS patients.

I think this is probably the best evidence we can get that what we see in mouse models of the disease is also happening in human patients, said the studys senior author, Serge Przedborski, MD, PhD, the Page and William Black Professor of Neurology (in Pathology and Cell Biology), Vice Chair for Research in the department of Neurology, and co-director of Columbias Motor Neuron Center.

The findings also are significant because they apply to the most common form of ALS, which affects about 90 percent of patients. Scientists do not know why ALS develops in these patients; the other 10 percent of patients carry one of 27 genes known to cause the disease.

Now that we know that the toxin is common to most patients, it gives us an impetus to track down this factor and learn how it kills the motor neurons, Dr. Przedborski said. Its identification has the potential to reveal new ways to slow down or stop the destruction of the motor neurons.

In the study, Dr. Przedborski and study co-authors Diane Re, PhD, and Virginia Le Verche, PhD, associate research scientists, removed astrocytes from the brain and spinal cords of six ALS patients shortly after death and placed the cells in petri dishes next to healthy motor neurons. Because motor neurons cannot be removed from human subjects, they had been generated from human embryonic stem cells in the Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research, also at CUMC.

Within two weeks, many of the motor neurons had shrunk and their cell membranes had disintegrated; about half of the motor neurons in the dish had died. Astrocytes removed from people who died from causes other than ALS had no effect on the motor neurons. Nor did other types of cells taken from ALS patients.

Astrocytes from ALS patients release a toxin that kills human motor neurons. Left: a disintegrating motor neuron on top of human astrocytes (blue). Right: a healthy motor neuron on top of astrocytes from people unaffected by ALS. Image: Diane Re.

Read more:
Medical Center Researchers Create Human ALS Model That May Lead to New Therapies

A new method of producing stem cells is being described as a "game-changing" scientific breakthrough.

It is said that the research, carried out by scientists in Japan, could hail a new era of personalised medicine, offering hope to sufferers of diseases such as stroke, heart disease and spinal cord injuries.

The scientists bathed blood cells in a weak acidic solution for half an hour, which made the adult cells shrink and go back to their embryonic stem cell state. Using this process, a patient's own specially created stem cells could then be re-injected back into the body to help mend damaged organs.

The scientists in Japan used mice in this experiment but believe the approach may also work on human cells too.

The new method - much cheaper and faster than before - is being heralded as revolutionary, and could bring stem cell therapy a step closer, and all without the controversy linked to the use of human embryos.

But there is still research that some find ethically questionable.

On Inside Story: Is the controversy over using human embryos over? And how should ethics determine medical progress?

Presenter: Shiulie Ghosh

Guests:

Dusko Ilic, a reader in Stem Cell Science at King's College London School ofMedicine

Go here to read the rest:
The ethics of medical progress

PUBLIC RELEASE DATE:

30-Jan-2014

Contact: Tom Vasich tmvasich@uci.edu 949-824-6455 University of California - Irvine

Irvine, Calif., Jan. 30, 2014 Two UC Irvine research teams will receive $1.54 million to further studies on the fundamental structure and function of stem cells. Their work will aid efforts to treat and cure a range of ailments, from cancer to neurological diseases and injuries.

The California Institute for Regenerative Medicine awarded the two grants today to Lisa Flanagan and Peter Donovan of the Sue & Bill Gross Stem Cell Research Center as part of its basic biology awards program.

CIRM's governing board gave 27 such grants worth $27 million to 11 institutions statewide. The funded projects are considered critical to the institute's mission of investigating the underlying mechanisms of stem cell biology, cellular plasticity and cellular differentiation in order to create a foundation for future translational and clinical advances.

Today's grants bring total CIRM funding at UC Irvine to $98.8 million.

"Innovative basic research like this paves the way to better designs for the use of stem cells," said Sidney Golub, director of the Sue & Bill Gross Stem Cell Research Center. "Even more importantly, it can open up entirely new approaches based on a better understanding of how stem cells function."

In one project, Flanagan and her UC Irvine colleagues will utilize a $1 million grant to study what happens on the surface of early-stage neural stem cells that causes them to develop into either neurons or astrocytes different kinds of brain and spinal cord cells. In the course of this work, the team aims to uncover specific properties of human stem cells used to treat neurological diseases and injuries.

"We expect this knowledge will enhance the benefit of these cells in transplants by enabling more control over what sort of mature cells will be formed from transplanted cells," said Flanagan, an assistant professor of neurology, biomedical engineering and anatomy & neurobiology. "We hope our research will greatly improve the identification, isolation and utility of certain types of human neural stem cells."

Excerpt from:
UC Irvine stem cell researchers awarded $1.54 million in state funding

Professor Austin Smith of Cambridge University, writing in the Journal Nature said the new cells could be seen as a blank slate from which any cell could emerge depending on its environment.

Remarkably, instead of triggering cell death or tumour growth as might be expected, a new cell state emerges that exhibits and unprecedented potential for differentiation into every possible cell type, he said.

The discovery has been hailed as incredible by scientists who believe it will speed up the advancement of personalised medicine.

Stem cells offer the possibility of a renewable source of replacement cells and tissues to treat diseases including Alzheimer's, spinal cord injury, stroke, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.

They could be used to regenerate organs, stimulate the growth of new blood vessels, or create skin grafts.

(This) approach in the mouse is the most simple, lowest cost and quickest method to generate pluripotent cells from mature cells, said Professor Chris Mason, Chair of Regenerative Medicine Bioprocessing, at University College London.

If it works in man, this could be the game changer that ultimately makes a wide range of cell therapies available using the patients own cells as starting material the age of personalised medicine would have finally arrived.

Who would have thought that to reprogram adult cells to an embryonic stem cell-like (pluripotent) state just required a small amount of acid for less than half an hour an incredible discovery.

Professor Mason said the development was likely to speed up the development of technology in everyday clinical practice although warned that was still years away.

Dr Dusko Ilic, Reader in Stem Cell Science, Kings College London, said the findings were revolutionary.

View original post here:
'Stem cells' created in less than 30 minutes in 'groundbreaking' discovery

CALGARY- A Winnipeg paramedic has become the first Canadian to take part in an international clinical trial involving the treatment of spinal cord injuries using stem cells.

Alex Petric was injured last year during a winter vacation in Panama.

I misjudged the water and just dove in, the 29-year-old recalls. I hit shallow water and became paralyzed immediately.

Petric, now a paraplegic, became involved with the trial just four months after his injury.

Its a phase one trial which means that its looking at the safety and tolerability of the procedure, explains Dr. Steve Casha, medical team lead for the University of Calgary.

A Swiss company, calledStem Cells Incorporatedis the driving force behind the research. A team in Switzerland has already treated eight other spinal cord patients.

During the trial, researchers must first identify the precise location of Petrics spinal cord injury. Then, stem cells are injected into two sites above and two sites below the injury to hopefully recreate lost tissue.

What these cells will hopefully do, and what they seem to do from previous clinical studies is take up residence in the spinal cord. They are a self-renewing population and they can differentiate or become various cells, Dr. Casha explains.

While the first phase of the trial focuses on safety, the ultimate goal is to develop a cure for spinal cord injuries. So far, two patients in the study have regained sensation.

Petric says his expectations are realistic, but his dream is to walk again.

Originally posted here:
New trial offers new hope for those with spinal cord injuries

Eleven years ago, Megan Quinn had just gotten married and was the picture of health.

"I used to run five miles a day. All of a sudden on my third mile, I started dragging my foot and I didn't understand. I thought, I'm just getting old and I'm getting tired. I was 27 years old," she said. "Nothing ever clicked to me that something was wrong."

The diagnosis was multiple sclerosis.

Multiple sclerosis, or MS, is an autoimmune disease where the body attacks itself and damages myelin, the protective covering surrounding nerve cells. With that insulation compromised, the nerves deteriorate and can cause a wide range of symptoms including vision problems, fatigue and weakness. The disease affects as many as 350,000 Americans.

"For the past year I've had a really bad time with this disease, just with my hip not working. One night I woke up and I couldn't feel either of my legs," Quinn said.

"Right now, my biggest problem is my hamstring. I cannot get my hamstring to cooperate when I have to walk, so that's my battle right now," she said.

Current treatments only try to stop progression of the disease. Quinn is about to test a new approach: using stem cells designed to actually make MS patients better.

Stem cells can be morphed into any cell in the body. Patients like Quinn have bone marrow removed and the stem cells inside are then changed in the kind of stem cells found in the brain and spinal cord.

Those cells will then be injected directly into the spinal cord. The hope is that they will repair the insulation and perhaps even the wires underneath.

See more here:
MS patient to take part in pioneering experiment

Ann Murray

Ann Murray has been writing since 1990, with her work now appearing on various websites. She holds a Bachelor of Arts in writing and history from Bard College and is pursuing her Doctor of Philosophy in biology.

Stem cells are the cells from which all other cells in the body are created. Embryonic stem cells are particularly versatile, as they are pluripotent. This means they are able to transform into any other cell type, including another stem cell. Stem cells are currently being studied as a potential treatment for spinal injury and for degenerative diseases involving cell death or dysfunction.

Parkinson's disease is a degenerative neurological condition associated with motor control in humans. In 1817, British doctor James Parkinson discovered a disorder...

In the United States alone, there are about 400,000 patients with severe spinal cord injuries, resulting in whole or partial immobilization. About...

You've probably heard it from your parents or your teachers: Stand up straight and sit properly or you'll hurt your spine. Well,...

Stem cell therapies are designed to replace dysfunctional or diseased cells with healthy ones. Embryonic stem cells, the non-specialized or "starter" cells...

As illustrated by the photograph, the brain has three protective layers referred to as meninges. The mid layer, referred to as the...

According to the Mayo Clinic, since the 1960s, doctors have performed transplants of stem cells---often referred to as bone marrow---to treat cancer....

The use of stem cells as a treatment cure is an ongoing area of development and political debate. Both adult and embryonic...

Read more:
Stem Cell Spinal Treatment | eHow - eHow | How to Videos ...

Indian J Orthop. 2012 Jan-Feb; 46(1): 1018.

Department of University Health Network, Toronto Western Hospital, Toronto, Canada, ON M5T 2S8

Address for correspondence: Dr. Michael Fehlings, University Health Network, Toronto Western Research Institute, Main Pavilion, 12th Floor, 399 Bathurst Street, Toronto, Canada ON M5T 2S8. E-mail: michael.fehlings/at/uhn.ca

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Spinal cord injury (SCI) is a devastating condition associated with significant functional and sensory deficits, emotional, social, and financial burdens, and an increased risk of cardiovascular complications, deep vein thrombosis, osteoporosis, pressure ulcers, autonomic dysreflexia, and neuropathic pain.

The estimated annual global incidence of SCI is 1540 cases per million. In the USA, approximately 1.275 million individuals are affected, with over 12,000 new cases each year.15 The most common causes of traumatic SCI are road traffic accidents, falls, occupational and sports-related injuries that result in contusion and compression of the spinal cord.1 Approximately 55% of SCIs occur at the cervical level (C1 to C7-T1) with a mortality of 10% in the first year following injury and an expected lifespan of only 1015 years post-injury, and thoracic (T1T11), thoracolumbar (T11T12 to L1L2) and lumbosacral (L2S5) injuries each account for approximately 15% of SCI.14 Depending on the age of the patient, severity, and levels of SCI, the lifetime cost of health care and other injury-related expenses can reach $25 million.15

Despite advances in pre-hospital care, medical and surgical management and rehabilitation approaches, many SCI sufferers still experience substantial neurological disability. Intensive efforts are underway to develop effective neuroprotective and regenerative strategies.

SCI involves a primary (the physical injury) and a secondary injury (the subsequent cascade of molecular and cellular events which amplify the original injury).6 The primary injury damages both upper and lower motor neurons and disrupts motor, sensory and autonomic functions. Pathophysiological processes occurring in the secondary injury phase are rapidly instigated in response to the primary injury in an attempt to homeostatically control and minimize the damage. Paradoxically, this response is largely responsible for exacerbating the initial damage and creating an inhibitory milieu that prevents endogenous efforts of repair, regeneration and remyelination. These secondary processes include inflammation, ischemia, lipid peroxidation, production of free radicals, disruption of ion channels, axonal demyelination, glial scarring (astrogliosis), necrosis and programmed cell death. Nevertheless, endogenous repair and regenerative mechanisms during the secondary phase of injury minimize the extent of the lesion (through astrogliosis), reorganize blood supply through angiogenesis, clear cellular debris, and reunite and remodel damaged neural circuits. The spatial and temporal dynamics of these secondary mediators7 are fundamental to SCI pathophysiology and as such offer exploitable targets for therapeutic intervention.

A multitude of characteristics of cells tested pre-clinically and clinically make them attractive to potentially address the multifactorial nature of the pathophysiology of secondary SCI they are anti-inflammatory, immunomodulatory,812 anti-gliotic,13 pro-oligodendrogliogenic,14 pro-neuronogenic,15 and secrete various anti-apoptotic and pro-angiogenic neurotrophic factors. Given the pathophysiological targets of SCI,7 transplanted cells should: 1) enable regenerating axons to cross barriers; 2) functionally replace lost cells; and/or 3) create an environment supportive of neural repair.16 However, given the multifactorial nature of SCI and its dynamic pathophysiological consequences, the success of future clinical trials of cell therapy will likely depend on the informed co-administration of multiple strategies, including pharmacological and rehabilitation therapies.7

Different sources and types of cells have been and/or are being tested in clinical trials for SCI, including embryonic stem cells (ESCs), neural progenitor cells (NPCs), bone marrow mesenchymal cells (BMSCs) and non-stem cells such as olfactory ensheathing cells and Schwann cells.17 Other cell types are being developed for the clinic, including other sources of mesenchymal cells (fetal blood,18 adipose tissue, umbilical cord1936), adult21,37 and immortalized neural progenitors (PISCES, NCT01151124), skin-derived progenitors,3847 induced pluripotent stem cells4852 and endogenous spinal cord progenitors5358 []. The advantages and disadvantages of each cell source and type being considered or already in clinical trials for SCI have been extensively described and compared elsewhere,17,5963 and reflect their potential in the clinic []. There are currently more than a dozen cell therapy clinical trials for SCI listed on clinicaltrials.gov.64 Most are Phase I or I/II clinical safety and feasibility studies, indicating that cellular treatments for SCI developed in the laboratory are still in the very early stages of clinical translation.

Original post:
Current stem cell treatments for spinal cord injury

Panama City, Panama (PRWEB) January 14, 2014

Translational Biosciences, a subsidiary of Medistem Panama has received the countys first clinical trial approval for the treatment of rheumatoid arthritis with human umbilical cord-derived mesenchymal stem cells (MSC) from the Comit Nacional de Biotica de la Investigacin Institutional Review Board (IRB).

Rheumatoid Arthritis (RA) is an autoimmune disease in which the patients immune system generates cellular and antibody responses to various components of the joint such as type I collagen. As a result of this immune response, not only does joint destruction occur, but also other secondary complications such as pulmonary fibrosis, renal damage, and even heart damage. RA affects approximately 0.5-1% of the population in the United States.

Mesenchymal stem cells harvested from donated human umbilical cords after normal, healthy births possess anti-inflammatory and immune modulatory properties that may relieve RA symptoms. Because they are immune privileged, the recipients immune system does not reject them. These properties make MSC interesting candidates for the treatment of rheumatoid arthritis and other autoimmune disorders.

Each patient will receive five intravenous injections of umbilical cord stem cells over the course of 5 days. They will be assessed at 3 months and 12 month primarily for safety and secondarily for indications of efficacy.

The stem cell technology being utilized in this trial was developed by Neil Riordan, PhD, founder of Medistem Panama. The stem cells will be harvested and processed at Medistem Panamas 8000 sq. ft. laboratory in the prestigious City of Knowledge. They will be administered at the Stem Cell Institute in Panama City, Panama.

The Principle Investigator is Jorge Paz-Rodriguez, MD. Dr. Paz-Rodriguez also serves as the Medical Director at the Stem Cell Institute.

While this is just the first step, it is our hope that Panamas rapid emergence as a leader in applied stem cell research will lead to safe, effective treatments for debilitating diseases such as rheumatoid arthritis and serve to benefit all Panamanians who suffer from it in the not-too-distant future, said Ruben Berocal, M.D., National Secretary of Science, Technology and Innovation (SENACYT). Oversight by the National Committee for Investigational Bioethics ensures patient safety by demanding ethical transparency and compliance with the highest levels of international standards, he added.

For detailed information about this clinical trial visit http://www.clinicaltrials.gov. If you are a rheumatoid arthritis patient who has not responded to disease modifying anti-rheumatic drugs (DMARD) for at least 6 months you may qualify for this trial. Please email trials(at)translationalbiosciences(dot)com for more information about how to apply.

About Translational Biosciences

See more here:
Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de ...

CTVNews.ca Staff Published Friday, January 10, 2014 4:33PM EST Last Updated Friday, January 10, 2014 11:42PM EST

A team of doctors at the University of Calgary has, for the first time in North America, successfully performed a stem cell transplant in a spinal cord injury patient, a procedure that could offer a glimmer of hope to patients whose injuries have long been considered untreatable.

The doctors injected the neural stem cells into the spine of a 29-year-old paraplegic, who will now be monitored to determine whether implanting those cells is safe.

Later studies will look at whether it is possible to regenerate new tissue and repair the mans injury.

That is the goal, a cure, the University of Calgarys Dr. Steven Casha, who performed the procedure on Wednesday, told CTV News.

Stem cells have the potential to recreate lost tissue, he added, although that remains to be proven in humans with spinal cord injuries. The answer, he said, is a long way away.

The transplant is part of an ongoing clinical trial being conducted by StemCells Inc., which harvested the stem cells from the nervous system of a fetus. The company holds a patent on the cells.

Data from three patients in Europe who have already undergone a transplant suggests the procedure is safe.

We have not been seeing significant complications or adverse eventsand there have been a couple of patients who havemade very small gains in functionthat appear to be hopeful and that is very interesting, Dr. Michael Fehlings, head of the spinal program at Toronto Western Hospital and the lead investigator for the trial at the University of Toronto, told CTV.

Fehlings cautioned that the results are very preliminary.

Excerpt from:
Start of stem-cell study offers hope to patients with spinal-cord injuries

Ryan White, CTV Calgary Published Friday, January 10, 2014 3:37PM MST Last Updated Friday, January 10, 2014 7:10PM MST

Alex Petric is hoping his part in an international clinical trial at the Foothills Hospital will assist researchers in the development of a treatment for spinal cord injuries.

Alex, a paramedic from Winnipeg, was paralyzed during a winter holiday in Panama with his girlfriend. The 28-year-old dove headfirst into what he believed to be deep water.

Immediately I felt paralyzed, right when I came up, recollects Alex. You just know youre in a lot of trouble. Youre trying your hardest to move your legs and its not happening.

Ten months after the accident, 29-year-old Alex is taking part in a medical trial to determine the safety of stem cell therapy on patients with spinal cord injuries.

While the trial, conducted by researchers from the University of Calgary, focuses on safety, the ultimate goal is to develop a cure for spinal cord injuries which could require multiple therapies.

The medical team, led by Dr. Steve Casha, will make a small incision in order to view Alexs injury. Once the precise location of the injury has been determined, then stem cells are injected above and below to potentially recreate the lost tissue.

The approach is regeneration, explains Dr. Casha, to reverse the damage that has been done.

Researchers and Alex are realistic in their expectations of the treatment despite the fact two previous patients in the study have regained sensation.

I just feel like I am part of something that could give people hope, including myself, said Alex. We don't know what will happen with this surgery. They're trying to fix us, basically trying to make us normal again.

Read more from the original source:
Calgary medical team attempting stem cell therapy on paralyzed man

Jan. 10, 2014

A team of engineers at the University of Wisconsin-Madison has created a process to improve the creation of synthetic neural stem cells for use in central nervous system research.

The process, outlined in a paper published in Stem Cells last month, will improve the state of the art in the creation of synthetic neural stem cells for use in central nervous system research.

Randolph Ashton

Human pluripotent stem cells have been used to reproduce nervous-system cells for use in the study and treatment of spinal cord injuries and of diseases such as Parkinson's and Huntington's.

Currently, most stem cells used in research have been cultured on mouse embryonic fibroblasts (MEFs), which require a high level of expertise to prepare. The expertise required has made scalability a problem, as there can be slight differences in the cells used from laboratory to laboratory, and the cells maintained on MEFs are also undesirable for clinical applications.

Removing the high level of required skill and thereby increasing the translatability of stem cell technology is one of the main reasons why Randolph Ashton, a UW-Madison assistant professor of biomedical engineering and co-author of the paper, wanted to create a new protocol.

Rather than culturing stem cells on MEFs, the new process uses two simple chemical cocktails to accomplish the same task. The first mixture, developed by John D. MacArthur Professor of Medicine James Thomson in the Morgridge Institute for Research, is used to maintain the stem cells in the absence of MEFs. The second cocktail allows researchers to push the stem cells toward a neural fate with very high efficiency.

These chemical mixtures help to ensure the consistency of the entire process and give researchers a better understanding of what is driving the differentiation of the cells. "Once you remove some of the confounding factors, you have better control and more freedom and flexibility in terms of pushing the neural stem cells into what you want them to become," says Ashton.

More here:
A shift in stem cell research

As scientists get closer to using embryonic stem cells in new treatments for blindness, spinal cord injuries and heart disease, a U.S. legal debate could determine who profits from that research.

Consumer Watchdog, a nonprofit advocacy group, wants an appeals court to invalidate a University of Wisconsin-Madisons patentfor stem cells derived from human embryos, saying its too similar to earlier research. The Santa Monica, California, group also says the U.S. Supreme Courts June ruling limiting ownership rights of human genes should apply to stem cells, a potentially lucrative field for medical breakthroughs.

The challenge to Wisconsin Alumni Research Foundation, the universitys licensing arm, is about whether patents help or hinder U.S. stem-cell research, which has been stymied by political debate. The consumer group says it drives up the cost of research by requiring companies and some academics to pay a licensing fee to the university.

What were asking the government to do is say WARF has no right to the patent, said Dan Ravicher, executive director Public Patent Foundation in New York, which is handling the challenge for Consumer Watchdog. Its like the government sent a check to WARF they didnt deserve.

Consumer Watchdog lost a challenge at the U.S. Patent and Trademark Office in January 2013. It wants the Court of Appeals for the Federal Circuit in Washington to review that decision and consider new arguments based on the Supreme Courts finding that genes -- like stem cells -- are a natural material that cant be patented. Beyond the science question, the case has become a flashpoint over how far members of the public can go to invalidate patents on policy grounds.

While the patent expires in April 2015 and the university has other stem-cell-related patents, Consumer Watchdog is continuing a six-year battle to invalidate it because stem-cell research is starting to get some traction into therapeutic uses, Ravicher said.

The promise of embryonic stem cells is to create or repair tissues and organs using material taken from eggs fertilized in the laboratory. The cells created can be replicated indefinitely, and with the right biological cues, may aid in treating damaged heart tissue and spinal cords, or generate therapies for diabetes and cancer. Companies like StemCells Inc. (STEM) and Advanced Cell Technology Inc. are testing therapies to treat macular degeneration, a cause of blindness.

The next paradigm shift in medicine will be advances in cell therapy -- its under way, said Jason Kolbert, senior biotechnology analyst with Maxim Group LLC in New York. He said pharmaceutical makers such as Teva Pharmaceutical Industries Ltd. (TEVA) of Petach Tikva, Israel, and Pfizer (PFE) Inc. of New York are working with stem-cell researchers on new therapies.

Stem-cell science in the U.S. was curbed in 2001 when then-President George W. Bush issued an executive order limiting research to existing cell lines amid controversy over human embryo destruction, even though they were never in a womans uterus. President Barack Obama reversed that order in 2009.

Some scientists have avoided the public debate by using adult cells to find the unlimited potential they have in embryonic cells.

See the original post here:
Gene Patent Case Fuels U.S. Court Test of Stem Cell Right